Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Novavax adds antigens to COVID-19 production pact with Indian vaccines giant
Defining COVID-19 immunity: CDC, EU researchers tap Siemens Healthineers to help standardize antibody tests
Healthcare roundup: Google donating $8.5M to COVID-19 data analytics, AI projects
Biopharma roundup: AZ cleared to test shot in more Brazilian patients; global vaccination push could take up to 5 years, SII chief says
PPD ups its revenue guidance after riding the tumultuous COVID-19 wave
MDLive banks $50M equity investment to scale up telehealth services
CMS planning to fully rely on encounter data for Medicare Advantage risk adjustment in 2022

Featured Story

Novavax adds antigens to COVID-19 production pact with Indian vaccines giant

By Kyle Blankenship

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause.

Defining COVID-19 immunity: CDC, EU researchers tap Siemens Healthineers to help standardize antibody tests

By Conor Hale

The project will help define the proper concentrations of antibodies necessary for a test to determine whether a person is immune to COVID-19.

Healthcare roundup: Google donating $8.5M to COVID-19 data analytics, AI projects

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: AZ cleared to test shot in more Brazilian patients; global vaccination push could take up to 5 years, SII chief says

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

AstraZeneca won the OK the test its shot in 5,000 additional Brazilian subjects. Global vaccination efforts may take up to five years, the Serum Institute's Adar Poonawalla said. South Korea will spend $146 million to lock down vaccines for 60% of its population. Plus, researchers are developing treatments to strike COVID-19 in the nose.

PPD ups its revenue guidance after riding the tumultuous COVID-19 wave

By Ben Adams

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.

MDLive banks $50M equity investment to scale up telehealth services

By Heather Landi

Riding the wave of investor interest in virtual care, MDLive banked a $50 million crossover equity investment led by Sixth Street Growth. Find out why CEO Charles Jones believes competitor Teladoc's blockbuster deal will spur more consolidation in the market, including acquisition opportunities for his own company.

CMS planning to fully rely on encounter data for Medicare Advantage risk adjustment in 2022

By Paige Minemyer

CMS said it plans to begin in 2022 using solely encounter data to calculate risk adjustment in Medicare Advantage and Part D.

COVID-19 Tracker